| Year |
Citation |
Score |
| 2023 |
Auchynnikava T, Äärelä A, Liljenbäck H, Järvinen J, Andriana P, Kovacs L, Rautio J, Rajander J, Virta P, Roivainen A, Li XG, Airaksinen AJ. Tetrazine Glycoconjugate for Pretargeted Positron Emission Tomography Imaging of -Cyclooctene-Functionalized Molecular Spherical Nucleic Acids. Acs Omega. 8: 45326-45336. PMID 38075748 DOI: 10.1021/acsomega.3c04041 |
0.327 |
|
| 2023 |
Otaru S, Martinmäki T, Kuurne I, Paulus A, Helariutta K, Sarparanta M, Airaksinen AJ. Radiolabelling of peptides with tetrazine ligation based on the inverse electron-demand Diels-Alder reaction: rapid, catalyst-free and mild conversion of 1,4-dihydropyridazines to pyridazines. Rsc Advances. 13: 22606-22615. PMID 37501774 DOI: 10.1039/d3ra02807k |
0.665 |
|
| 2022 |
Lambidis E, Chen CC, Lumén D, Sánchez AIF, Sarparanta M, Cheng RH, Airaksinen AJ. Biological evaluation of integrin αβ-targeted Ga-labeled HEVNPs in HCT 116 colorectal tumor-bearing mice. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 106336. PMID 36403717 DOI: 10.1016/j.ejps.2022.106336 |
0.662 |
|
| 2022 |
Lambidis E, Chen CC, Baikoghli M, Imlimthan S, Khng YC, Sarparanta M, Cheng RH, Airaksinen AJ. Development of Ga-Labeled Hepatitis E Virus Nanoparticles for Targeted Drug Delivery and Diagnostics with PET. Molecular Pharmaceutics. PMID 35857429 DOI: 10.1021/acs.molpharmaceut.2c00359 |
0.68 |
|
| 2022 |
Otaru S, Paulus A, Imlimthan S, Kuurne I, Virtanen H, Liljenbäck H, Tolvanen T, Auchynnikava T, Roivainen A, Helariutta K, Sarparanta M, Airaksinen AJ. Development of [F]AmBF Tetrazine for Radiolabeling of Peptides: Preclinical Evaluation and PET Imaging of [F]AmBF-PEG-Tyr-Octreotide in an AR42J Pancreatic Carcinoma Model. Bioconjugate Chemistry. PMID 35709482 DOI: 10.1021/acs.bioconjchem.2c00231 |
0.699 |
|
| 2022 |
Lambidis E, Lumén D, Koskipahta E, Imlimthan S, Lopez BB, Sánchez AIF, Sarparanta M, Cheng RH, Airaksinen AJ. Synthesis and ex vivo biodistribution of two Ga-labeled tetrazine tracers: Comparison of pharmacokinetics. Nuclear Medicine and Biology. PMID 35680503 DOI: 10.1016/j.nucmedbio.2022.05.004 |
0.678 |
|
| 2022 |
Lumen D, Vugts D, Chomet M, Imlimthan S, Sarparanta M, Vos R, Schreurs M, Verlaan M, Lang PA, Hippeläinen E, Beaino W, Windhorst AD, Airaksinen AJ. Pretargeted PET Imaging with a TCO-Conjugated Anti-CD44v6 Chimeric mAb U36 and [Zr]Zr-DFO-PEG-Tz. Bioconjugate Chemistry. PMID 35442642 DOI: 10.1021/acs.bioconjchem.2c00164 |
0.695 |
|
| 2021 |
Imlimthan S, Khng YC, Keinänen O, Zhang W, Airaksinen AJ, Kostiainen MA, Zeglis BM, Santos HA, Sarparanta M. A Theranostic Cellulose Nanocrystal-Based Drug Delivery System with Enhanced Retention in Pulmonary Metastasis of Melanoma. Small (Weinheim An Der Bergstrasse, Germany). e2007705. PMID 33738957 DOI: 10.1002/smll.202007705 |
0.754 |
|
| 2021 |
Das S, Imlimthan S, Airaksinen AJ, Sarparanta M. Radiolabeling of Theranostic Nanosystems. Advances in Experimental Medicine and Biology. 1295: 49-76. PMID 33543455 DOI: 10.1007/978-3-030-58174-9_3 |
0.714 |
|
| 2021 |
Matović J, Järvinen J, Sokka IK, Imlimthan S, Raitanen JE, Montaser A, Maaheimo H, Huttunen KM, Peräniemi S, Airaksinen AJ, Sarparanta M, Johansson MP, Rautio J, Ekholm FS. Exploring the Biochemical Foundations of a Successful GLUT1-Targeting Strategy to BNCT: Chemical Synthesis and Evaluation of the Entire Positional Isomer Library of -Carboranylmethyl-Bearing Glucoconjugates. Molecular Pharmaceutics. 18: 285-304. PMID 33390018 DOI: 10.1021/acs.molpharmaceut.0c00917 |
0.677 |
|
| 2020 |
Lumen D, Wang S, Mäkilä E, Imlimthan S, Sarparanta M, Correia A, Westerveld Haug C, Hirvonen J, Santos HA, Airaksinen AJ, Filtvedt W, Salonen J. Investigation of silicon nanoparticles produced by centrifuge chemical vapor deposition for applications in therapy and diagnostics. European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V. PMID 33279602 DOI: 10.1016/j.ejpb.2020.11.022 |
0.674 |
|
| 2020 |
Matović J, Järvinen J, Bland HC, Sokka IK, Imlimthan S, Mateu Ferrando R, Huttunen KM, Timonen J, Peräniemi S, Aitio O, Airaksinen AJ, Sarparanta M, Johansson MP, Rautio J, Ekholm FS. Addressing the Biochemical Foundations of a Glucose-based "Trojan horse"-strategy to Boron Neutron Capture Therapy: From Chemical Synthesis to In Vitro Assessment. Molecular Pharmaceutics. PMID 32787269 DOI: 10.1021/Acs.Molpharmaceut.0C00630 |
0.674 |
|
| 2020 |
Otaru S, Niemikoski H, Sarparanta M, Airaksinen AJ. Metabolism of a Bioorthogonal PET Tracer Candidate [19F/18F]SiFA-Tetrazine in Mouse Liver Microsomes: Biotransformation Pathways and Defluorination Investigated by UHPLC-HRMS. Molecular Pharmaceutics. PMID 32539414 DOI: 10.1021/Acs.Molpharmaceut.0C00523 |
0.699 |
|
| 2020 |
Jakobsson U, Mäkilä E, Rahikkala A, Imlimthan S, Lampuoti J, Ranjan S, Heino J, Jalkanen P, Köster U, Mizohata K, Santos HA, Salonen J, Airaksinen AJ, Sarparanta M, Helariutta K. Preparation and in vivo evaluation of red blood cell membrane coated porous silicon nanoparticles implanted with Tb. Nuclear Medicine and Biology. 84: 102-110. PMID 32334356 DOI: 10.1016/J.Nucmedbio.2020.04.001 |
0.675 |
|
| 2020 |
Otaru S, Imlimthan S, Sarparanta M, Helariutta K, Wähälä K, Airaksinen AJ. Evaluation of Organo [F]Fluorosilicon Tetrazine as a Prosthetic Group for the Synthesis of PET Radiotracers. Molecules (Basel, Switzerland). 25. PMID 32156020 DOI: 10.3390/Molecules25051208 |
0.707 |
|
| 2020 |
Balasubramanian V, Domanskyi A, Renko JM, Sarparanta M, Wang CF, Correia A, Mäkilä E, Alanen OS, Salonen J, Airaksinen AJ, Tuominen R, Hirvonen J, Airavaara M, Santos HA. Engineered antibody-functionalized porous silicon nanoparticles for therapeutic targeting of pro-survival pathway in endogenous neuroblasts after stroke. Biomaterials. 227: 119556. PMID 31670035 DOI: 10.1016/J.Biomaterials.2019.119556 |
0.677 |
|
| 2019 |
Lumen D, Näkki S, Imlimthan S, Lambidis E, Sarparanta M, Xu W, Lehto VP, Airaksinen AJ. Site-Specific In-Radiolabeling of Dual-PEGylated Porous Silicon Nanoparticles and Their In Vivo Evaluation in Murine 4T1 Breast Cancer Model. Pharmaceutics. 11. PMID 31861119 DOI: 10.3390/Pharmaceutics11120686 |
0.688 |
|
| 2019 |
Imlimthan S, Correia A, Figueiredo P, Lintinen K, Balasubramanian V, Airaksinen AJ, Kostiainen MA, Santos HA, Sarparanta M. Systematic In Vitro Biocompatibility Studies of Multimodal Cellulose Nanocrystal and Lignin Nanoparticles. Journal of Biomedical Materials Research. Part A. PMID 31794149 DOI: 10.1002/Jbm.A.36856 |
0.696 |
|
| 2019 |
Nag S, Krasikova R, Airaksinen AJ, Arakawa R, Petukhovd M, Gulyas B. Synthesis and biological evaluation of [F]fluorovinpocetine, a potential PET radioligand for TSPO imaging. Bioorganic & Medicinal Chemistry Letters. PMID 31257082 DOI: 10.1016/j.bmcl.2019.06.037 |
0.3 |
|
| 2018 |
Imlimthan S, Otaru S, Keinänen O, Correia A, Lintinen KS, Santos HA, Airaksinen AJ, Kostiainen MA, Sarparanta M. Radiolabeled Molecular Imaging Probes for the in Vivo Evaluation of Cellulose Nanocrystals for Biomedical Applications. Biomacromolecules. PMID 30380842 DOI: 10.1021/Acs.Biomac.8B01313 |
0.781 |
|
| 2018 |
Keinänen O, Partelová D, Alanen O, Antopolsky M, Sarparanta M, Airaksinen AJ. Efficient cartridge purification for producing high molar activity F-glycoconjugates via oxime formation. Nuclear Medicine and Biology. 67: 27-35. PMID 30380464 DOI: 10.1016/J.Nucmedbio.2018.10.001 |
0.771 |
|
| 2018 |
Karaman DŞ, Sarparanta MP, Rosenholm JM, Airaksinen AJ. Multimodality Imaging of Silica and Silicon Materials In Vivo. Advanced Materials (Deerfield Beach, Fla.). PMID 29388264 DOI: 10.1002/adma.201703651 |
0.687 |
|
| 2017 |
Keinänen O, Fung K, Pourat J, Jallinoja V, Vivier D, Pillarsetty NK, Airaksinen AJ, Lewis JS, Zeglis BM, Sarparanta M. Pretargeting of internalizing trastuzumab and cetuximab with a 18F-tetrazine tracer in xenograft models. Ejnmmi Research. 7: 95. PMID 29198065 DOI: 10.1186/S13550-017-0344-6 |
0.737 |
|
| 2017 |
Keinänen O, Mäkilä EM, Lindgren R, Virtanen H, Liljenbäck H, Oikonen V, Sarparanta M, Molthoff C, Windhorst AD, Roivainen A, Salonen JJ, Airaksinen AJ. Pretargeted PET Imaging of trans-Cyclooctene-Modified Porous Silicon Nanoparticles. Acs Omega. 2: 62-69. PMID 28649670 DOI: 10.1021/acsomega.6b00269 |
0.791 |
|
| 2016 |
Keinänen O, Li XG, Chenna NK, Lumen D, Ott J, Molthoff CF, Sarparanta M, Helariutta K, Vuorinen T, Windhorst AD, Airaksinen AJ. A New Highly Reactive and Low Lipophilicity Fluorine-18 Labeled Tetrazine Derivative for Pretargeted PET Imaging. Acs Medicinal Chemistry Letters. 7: 62-6. PMID 26819667 DOI: 10.1021/Acsmedchemlett.5B00330 |
0.784 |
|
| 2015 |
Wang CF, Sarparanta MP, Mäkilä EM, Hyvönen ML, Laakkonen PM, Salonen JJ, Hirvonen JT, Airaksinen AJ, Santos HA. Multifunctional porous silicon nanoparticles for cancer theranostics. Biomaterials. 48: 108-18. PMID 25701036 DOI: 10.1016/j.biomaterials.2015.01.008 |
0.708 |
|
| 2015 |
Yrjölä S, Sarparanta M, Airaksinen AJ, Hytti M, Kauppinen A, Pasonen-Seppänen S, Adinolfi B, Nieri P, Manera C, Keinänen O, Poso A, Nevalainen TJ, Parkkari T. Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 67: 85-96. PMID 25447744 DOI: 10.1016/J.Ejps.2014.11.003 |
0.75 |
|
| 2014 |
Kallinen AM, Sarparanta MP, Liu D, Mäkilä EM, Salonen JJ, Hirvonen JT, Santos HA, Airaksinen AJ. In vivo evaluation of porous silicon and porous silicon solid lipid nanocomposites for passive targeting and imaging Molecular Pharmaceutics. 11: 2876-2886. PMID 24977922 DOI: 10.1021/mp500225b |
0.735 |
|
| 2014 |
Kallinen A, Todorov B, Kallionpää R, Bäck S, Sarparanta M, Raki M, García-Horsman JA, Bergström KA, Wallén EA, Männistö PT, Airaksinen AJ. Synthesis and biological evaluation of novel (123)I-labeled 4-(4-iodophenyl)butanoyl-L-prolyl-(2S)-pyrrolidines for imaging prolyl oligopeptidase in vivo. European Journal of Medicinal Chemistry. 79: 436-45. PMID 24763264 DOI: 10.1016/J.Ejmech.2014.04.014 |
0.692 |
|
| 2014 |
Wang CF, Mäkilä EM, Kaasalainen MH, Liu D, Sarparanta MP, Airaksinen AJ, Salonen JJ, Hirvonen JT, Santos HA. Copper-free azide-alkyne cycloaddition of targeting peptides toporous silicon nanoparticles for intracellular drug uptake Biomaterials. 35: 1257-1266. PMID 24211082 DOI: 10.1016/j.biomaterials.2013.10.065 |
0.703 |
|
| 2013 |
Mori MM, Airaksinen AJ, Hirvonen JT, Santos HA, Caramella CM. Evaluation of the physicochemical and biopharmaceutical properties of fluoro-indomethacin. Current Drug Metabolism. 14: 80-9. PMID 22497567 |
0.321 |
|
| 2012 |
Bimbo LM, Sarparanta M, Mäkilä E, Laaksonen T, Laaksonen P, Salonen J, Linder MB, Hirvonen J, Airaksinen AJ, Santos HA. Cellular interactions of surface modified nanoporous silicon particles. Nanoscale. 4: 3184-92. PMID 22508528 DOI: 10.1039/C2Nr30397C |
0.655 |
|
| 2012 |
Rajecki M, Sarparanta M, Hakkarainen T, Tenhunen M, Diaconu I, Kuhmonen V, Kairemo K, Kanerva A, Airaksinen AJ, Hemminki A. SPECT/CT imaging of hNIS-expression after intravenous delivery of an oncolytic adenovirus and 131I. Plos One. 7: e32871. PMID 22412937 DOI: 10.1371/Journal.Pone.0032871 |
0.65 |
|
| 2012 |
Sarparanta MP, Bimbo LM, Mäkilä EM, Salonen JJ, Laaksonen PH, Helariutta AM, Linder MB, Hirvonen JT, Laaksonen TJ, Santos HA, Airaksinen AJ. The mucoadhesive and gastroretentive properties of hydrophobin-coated porous silicon nanoparticle oral drug delivery systems. Biomaterials. 33: 3353-62. PMID 22285465 DOI: 10.1016/j.biomaterials.2012.01.029 |
0.678 |
|
| 2012 |
Sarparanta M, Bimbo LM, Rytkönen J, Mäkilä E, Laaksonen TJ, Laaksonen P, Nyman M, Salonen J, Linder MB, Hirvonen J, Santos HA, Airaksinen AJ. Intravenous delivery of hydrophobin-functionalized porous silicon nanoparticles: stability, plasma protein adsorption and biodistribution. Molecular Pharmaceutics. 9: 654-63. PMID 22277076 DOI: 10.1021/Mp200611D |
0.71 |
|
| 2011 |
Sarparanta M, Mäkilä E, Heikkilä T, Salonen J, Kukk E, Lehto VP, Santos HA, Hirvonen J, Airaksinen AJ. ¹⁸F-labeled modified porous silicon particles for investigation of drug delivery carrier distribution in vivo with positron emission tomography. Molecular Pharmaceutics. 8: 1799-806. PMID 21875120 DOI: 10.1021/Mp2001654 |
0.715 |
|
| 2011 |
Sarparanta M, Bimbo LM, Mäkilä E, Salonen J, Laaksonen T, Hirvonen J, Lehto V, Laaksonen P, Linder MB, Airaksinen AJ, Santos HA. Fluorine-18 radiolabeling as a tool to evaluate novel porous silicon based nano- and microcarriers for drug delivery Journal of Labelled Compounds and Radiopharmaceuticals. 54. DOI: 10.1002/Jlcr.1926 |
0.67 |
|
| 2010 |
Bimbo LM, Sarparanta M, Santos HA, Airaksinen AJ, Mäkilä E, Laaksonen T, Peltonen L, Lehto VP, Hirvonen J, Salonen J. Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats. Acs Nano. 4: 3023-32. PMID 20509673 DOI: 10.1021/Nn901657W |
0.699 |
|
| 2009 |
Hakkarainen T, Rajecki M, Sarparanta M, Tenhunen M, Airaksinen AJ, Desmond RA, Kairemo K, Hemminki A. Targeted radiotherapy for prostate cancer with an oncolytic adenovirus coding for human sodium iodide symporter. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5396-403. PMID 19706820 DOI: 10.1158/1078-0432.Ccr-08-2571 |
0.644 |
|
| Show low-probability matches. |